Novel CXCR3 antagonists with a piperazinyl-piperidine core
Brian F McGuinness1, Carolyn DiIanni Carroll, Lisa Guise Zawacki
1Ligand Pharmaceuticals, 3000 Eastpark Boulevard, Cranbury, NJ 08512, USA. bmcguinness@ligand.com
Bioorganic & Medicinal Chemistry Letters
|August 4, 2009
Summary
Researchers discovered new CXCR3 antagonists using aryl piperazine libraries. Structure-activity relationship studies identified key molecular features for potent CXCR3 antagonism.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Immunology
Background:
- Chemokine receptor type 3 (CXCR3) is a key target in inflammatory diseases.
- Developing selective CXCR3 antagonists is crucial for therapeutic intervention.
Purpose of the Study:
- To identify novel CXCR3 antagonists.
- To explore the structure-activity relationships of piperazinyl-piperidine derivatives as CXCR3 antagonists.
Main Methods:
- High-throughput screening of an encoded combinatorial aryl piperazine library.
- Synthesis of analogs using solid and solution phase methods.
- Evaluation of CXCR3 binding affinity and structure-activity relationships.
Main Results:
- Identification of a novel series of potent piperazinyl-piperidine based CXCR3 antagonists.
- Structure-activity relationship studies revealed essential molecular features for CXCR3 antagonism.
- Various functional groups were found to significantly influence compound potency.
Conclusions:
- Piperazinyl-piperidine scaffolds represent a promising class of CXCR3 antagonists.
- Understanding structure-activity relationships facilitates the design of more potent and selective CXCR3 inhibitors.
- These findings contribute to the development of new therapeutics for CXCR3-mediated conditions.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Drug-Receptor Interaction: Antagonist
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...